The first
oncolytic virus therapy (talimogene laherparepvec or TVEC) in the U.S. was
approved in October 2015 for the treatment of advanced melanoma patients.
Such novel and
safer treatments are in active development but not yet available for brain
tumors. Glioblastoma multiforme (GBM) is the most common and
aggressive form of brain cancer in adults with
median survival of less than 15 months.
Current radiotherapy
and chemotherapy regimens not only have failed to significantly benefit
high-grade tumor patients, but also are associated with severe long-term side
effects that worsen the quality of life.
No comments:
Post a Comment